PS-341 in Treating Patients With Metastatic Kidney Cancer
Completed · Phase 2
Conditions studied: Kidney Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of PS-341 is more effective in treating metastatic kidney cancer. PURPOSE: Randomized phase III trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney cancer.
Key facts
- Study ID
- NCT00025376
- Run by
- University of Chicago
- People needed
- 23
- Starts
- 2001-10-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2013-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- LaGrange Memorial Hospital — LaGrange, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
- Oncology Care Associates, P.L.L.C. — Saint Joseph, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.